Andy C. Rawstron

Chronic lymphocytic leukaemia (CLL) and CLL‐type monoclonal B‐cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing

Jane Shingles, J. Shingles, R. de Tute, 2010, Cytometry. Part B, Clinical cytometry.

Prevalence of monoclonal B‐cell lymphocytosis: A systematic review

G. Marti, A. Órfão, N. Caporaso, 2010, Cytometry. Part B, Clinical cytometry.

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

R. de Tute, A. Rawstron, R. Owen, 2016, Cytometry. Part B, Clinical cytometry.

Assessment of minimal residual disease in myeloma and the need for a consensus approach

M. Stetler-Stevenson, B. Paiva, A. Rawstron, 2016, Cytometry. Part B, Clinical cytometry.

IgM myeloma: a rare entity characterized by a CD20−CD56−CD117− immunophenotype and the t(11;14)

M. Drayson, F. Ross, G. Cook, 2008, British journal of haematology.

Minimal residual disease monitoring in multiple myeloma: flow cytometry is the method of choice

A. Rawstron, R. Owen, Andy C. Rawstron, 2005, British journal of haematology.

Sequential minimal residual disease (MRD) monitoring: Results from the UK Myeloma XI trial

G. Morgan, W. Gregory, M. Drayson, 2019, Clinical Lymphoma Myeloma and Leukemia.

Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens

A. Rawstron, P. Hillmen, R. Tute, 2006, Leukemia.